Pathos AI raises $237M at a $3B valuation, led by Bristol Myers Squibb
Pathos AI closed a $237 million Series E at a valuation of about $3 billion, led by Bristol Myers Squibb. Endpoints reports the round came in below the roughly $300 million the company had sought. The company says the money will expand its AI drug-development platform and advance its oncology pipeline. STAT reports Tempus AI is supplying new datasets and that a collaboration with BMS will first focus on Alzheimer's treatments, taking Pathos beyond oncology.
Why it's notable: A large pharma company leading the round, and a data supplier in Tempus joining it, shows AI drug developers building ties with the data and drug companies that run clinical trials. The planned move from oncology into neurology widens the platform's reach.